Drug intelligence / Profile preview

23ND04

Development stage: Preclinical
Lead developer: HK inno.N Corporation
Modality: Small Molecules

Overview

23ND04 is a discovery-stage small molecule oncology candidate being developed by HK inno.N (formerly CJ Healthcare). As of early 2026, the asset is in the early research and discovery phase of development. While it is designated for the treatment of cancer, specific details regarding its molecular target, mechanism of action, or the specific types of malignancies it is intended to treat have not yet been publicly disclosed by the company. It represents part of HK inno.N's strategic expansion into the oncology therapeutic area.

Beyond the preview

Go deeper on 23ND04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 23ND04.

Explore the full profile